Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)

NCT03428217 is registered in ClinicalTrials.gov with Calithera Biosciences, Inc as lead sponsor.

NCT NCT03428217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03428217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Lead sponsor
Calithera Biosciences, Inc
Phase
Phase 2
Overall status
Completed
Start date
April 24, 2018
Completion date
July 16, 2021
Enrollment
444 (actual)
Sites
133

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma, metastatic renal cell carcinoma